Early Switching Strategies in Antidepressant Non-Responders: Current Evidence and Future Research Directions

被引:66
作者
Kudlow, Paul A. [1 ]
McIntyre, Roger S. [2 ,3 ]
Lam, Raymond W. [4 ,5 ]
机构
[1] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Univ Hlth Network, Head Mood Disorders Psychopharmacol Unit, Toronto, ON, Canada
[4] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada
[5] Univ British Columbia Hosp, Mood Disorders Ctr Excellence, Vancouver, BC V6T 2A1, Canada
基金
加拿大健康研究院;
关键词
MAJOR DEPRESSIVE DISORDER; STAR-ASTERISK-D; EARLY IMPROVEMENT; EARLY PREDICTION; DOUBLE-BLIND; TIME-COURSE; FLUOXETINE; ONSET; TRAJECTORIES; GUIDELINES;
D O I
10.1007/s40263-014-0171-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Studies have found that up to two-thirds of patients with major depressive disorder (MDD) do not fully respond to the first antidepressant. While switching antidepressants is a common strategy for antidepressant non-responders, there is still a lack of consensus about the optimal timing of a switch. Many clinicians wait for 6-12 weeks before considering a switch. The objectives of this paper are to (1) review the evidence for positive and negative predictive value (NPV) of early improvement at 2-4 weeks to predict final antidepressant response; (2) review randomized controlled trials (RCTs) that examine early switching strategies; and (3) provide future research directions and clinical recommendations for timing of antidepressant switching. We conducted a literature search for English-language studies via PubMed and Google Scholar, from 1984 to May 2013, with the following terms: 'antidepressants', 'MDD', 'time course', 'trajectory', 'early response', 'onset', 'delayed response', 'early improvement', 'predictors', 'switch', 'combination therapy', and 'augmentation'. Replicated evidence indicates that lack of early improvement (e.g. < 20 % reduction in a depression scale score) at 2-4 weeks can be an accurate predictor to identify eventual non-responders. The NPVs suggest that only about one in five patients with lack of improvement at 4 weeks will have a response by 8 weeks. Three RCTs examined early switch strategies, but results are inconsistent and comparisons limited by methodological differences. Future studies should incorporate a standard consensus definition of early improvement, discern whether the effect of early switching is specific to certain types of antidepressants, and determine whether early switch is superior to other strategies such as augmentation or combination. Notwithstanding these limitations, there is reasonable evidence to recommend earlier assessment for improvement. If there is no indication of early improvement at 2-4 weeks after starting an antidepressant, and taking into account other patient and clinical factors, a change in management can be considered.
引用
收藏
页码:601 / 609
页数:9
相关论文
共 47 条
  • [11] A descriptive analysis of quality of life using patient-reported measures in major depressive disorder in a naturalistic outpatient setting
    IsHak, Waguih William
    Balayan, Konstantin
    Bresee, Catherine
    Greenberg, Jared Matt
    Fakhry, Hala
    Christensen, Scott
    Rapaport, Mark Hyman
    [J]. QUALITY OF LIFE RESEARCH, 2013, 22 (03) : 585 - 596
  • [12] Katz MM, 2009, PSYCHOPHARMACOL BULL, V42, P94
  • [13] Kennedy SH, 2012, CURR PHARM DESIGN, V18, P5976
  • [14] Improvement within 2 weeks and later treatment outcomes in patients with depressive disorders: The CRESCEND study
    Kim, Jae-Min
    Kim, Seon-Young
    Stewart, Robert
    Yoo, Joon-An
    Bae, Kyung-Yeol
    Jung, Sung-Won
    Lee, Min-Soo
    Yim, Hyeon-Woo
    Jun, Tae-Youn
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2011, 129 (1-3) : 183 - 190
  • [15] Sleep architecture variation: a mediator of metabolic disturbance in individuals with major depressive disorder
    Kudlow, P. A.
    Cha, D. S.
    Lam, R. W.
    McIntyre, R. S.
    [J]. SLEEP MEDICINE, 2013, 14 (10) : 943 - 949
  • [16] Predicting Treatment Response in Major Depressive Disorder: The Impact of Early Symptomatic Improvement
    Kudlow, Paul A.
    Cha, Danielle S.
    McIntyre, Roger S.
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2012, 57 (12): : 782 - 788
  • [17] Recursive Subsetting to Identify Patients in the STAR*D: A Method to Enhance the Accuracy of Early Prediction of Treatment Outcome and to Inform Personalized Care
    Kuk, Anthony Y. C.
    Li, Jialiang
    Rush, A. John
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 (11) : 1502 - 1508
  • [18] Onset, time course and trajectories of Improvement with antidepressants
    Lam, Raymond W.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S492 - S498
  • [19] Clinical effectiveness: The importance of psychosocial functioning outcomes
    Lam, Raymond W.
    Filteau, Marie-Josee
    Milev, Roumen
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2011, 132 : S9 - S13
  • [20] Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. Ill. Pharmacotherapy
    Lam, Raymond W.
    Kennedy, Sidney H.
    Grigoriadis, Sophie
    McIntyre, Roger S.
    Milev, Roumen
    Ramasubbu, Rajamannar
    Parikh, Sagar V.
    Patten, Scott B.
    Ravindran, Arun V.
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2009, 117 : S26 - S43